https://drugdiscoveryandbiotech.com/biotech-principles-and-concepts daily 0.75 2025-01-14 https://drugdiscoveryandbiotech.com/biotech-principles-and-concepts/the-comparable-companies-comps-approach-and-its-application-to-biotech-company-valuation monthly 0.5 2025-01-14 https://drugdiscoveryandbiotech.com/biotech-principles-and-concepts/biotech-investing-introduction-to-discounted-cash-flow-dcf-analysis-for-biotech-valuation monthly 0.5 2025-01-13 https://drugdiscoveryandbiotech.com/biotech-principles-and-concepts/biotech-pharma-partnerships-and-acquisitions-accelerating-innovation-and-delivering-medicines-to-market-faster monthly 0.5 2024-12-16 https://drugdiscoveryandbiotech.com/biotech-principles-and-concepts/drivers-of-value-in-pre-revenue-biotech-companies-introduction monthly 0.5 2024-07-15 https://drugdiscoveryandbiotech.com/biotech-principles-and-concepts/biotech-company-valuation-part-1-understanding-value-and-valuation monthly 0.5 2024-12-16 https://drugdiscoveryandbiotech.com/principles-and-concepts daily 0.75 2025-01-08 https://drugdiscoveryandbiotech.com/principles-and-concepts/advanced-drug-modalities-part-3-antibody-drug-conjugates-adcs monthly 0.5 2024-05-10 https://images.squarespace-cdn.com/content/v1/653536fc271ea56714ee90c6/32b44ce3-8c50-45a1-bb7e-646a3d805f14/Figure_1.jpg Concepts and Principles - Advanced Drug Modalities Part 3: Antibody-Drug Conjugates (ADCs) - Make it stand out Figure 1. Left: Antibody-drug conjugate (ADC) overall structure: antibody moiety, linker, and payload. Right: Primary mechanism of action of ADCs. After recognizing its target antigen on the cancer cell surface, the ADC is internalized and the payload is released. The release of cytotoxic payloads inside the cancer cell leads to cell death. The released cytotoxic payload can cross the cell membrane and impact other cancer cells within the tumor microenvironment, a phenomenon referred to as the bystander effect. https://images.squarespace-cdn.com/content/v1/653536fc271ea56714ee90c6/d4ee89eb-15a7-4522-9e60-03ae5e490f29/Table_1.jpg Concepts and Principles - Advanced Drug Modalities Part 3: Antibody-Drug Conjugates (ADCs) - Make it stand out Table 1. Approved antibody-drug conjugate (ADC) therapies. https://images.squarespace-cdn.com/content/v1/653536fc271ea56714ee90c6/747a77d8-b3f8-4a38-a1fe-943a551282f2/Figure_2.jpg Concepts and Principles - Advanced Drug Modalities Part 3: Antibody-Drug Conjugates (ADCs) - Make it stand out Figure 2. Secondary immune system-mediated mechanisms of action of antibody-drug conjugates (ADCs). The Fc region of the antibody moiety can be recognized by specialized immune cells to elicit antibody-dependent cell-phagocytosis (ADCP) and antibody-dependent cell-mediated cytotoxicity (ADCC). The antibody moiety can also be recognized by C1q, a protein complex that activates the complement pathway leading to complement-dependent cytotoxicity (CDC) and resulting in cell death. https://drugdiscoveryandbiotech.com/principles-and-concepts/advanced-drug-modalities-part3-rna-therapeutic-modalities monthly 0.5 2024-03-17 https://images.squarespace-cdn.com/content/v1/653536fc271ea56714ee90c6/de06592c-c512-40c0-abe7-09ac971ae9ac/RNA+advanced+drug+modalities.jpg Concepts and Principles - Advanced Drug Modalities Part 2: Advanced RNA Therapeutic Modalities - Make it stand out Figure 1. Main mechanism of action of antisense oligonucleotides (ASOs, left) and small interfering RNAs (siRNAs, right). Mechanisms are simplified. Top left: ASO RNAse H-mediated RNA degradation. ASOs promote mRNA degradation by recruiting RNAse H after recognition of their mRNA target. Bottom left: ASO pre-mRNA splicing modulation. ASOs modulate pre-mRNA splicing by interacting with various exon and intron regions. Right: siRNAs target mRNAs for degradation . siRNA drugs are typically processed by the nuclease Dicer to generate activated siRNAs. The guide strand of siRNA, together with several proteins, form an RNA-induced silencing complex (RISC). The guide strand acts as a template to recognize target mRNA molecules, which are then cleaved by RISC. https://images.squarespace-cdn.com/content/v1/653536fc271ea56714ee90c6/f0ad595c-9817-4e42-9698-67e9f9e48c0a/Table+approved+ASO+therapeutics.jpg Concepts and Principles - Advanced Drug Modalities Part 2: Advanced RNA Therapeutic Modalities - Make it stand out Table 1. List of approved antisense oligonucleotide (ASO) therapeutics, together with their mechanism of action, indication, and year of approval. https://images.squarespace-cdn.com/content/v1/653536fc271ea56714ee90c6/051d1399-0d52-4c7e-87b4-930de05e40c3/Table+approved+siRNA+therapeutics.jpg Concepts and Principles - Advanced Drug Modalities Part 2: Advanced RNA Therapeutic Modalities - Make it stand out Table 2. List of approved siRNA therapeutics, together with their indication and year of approval. https://drugdiscoveryandbiotech.com/principles-and-concepts/advanced-drug-modalities-part-1-cell-therapies monthly 0.5 2024-02-18 https://images.squarespace-cdn.com/content/v1/653536fc271ea56714ee90c6/236d9c4e-f46b-4e33-9c1b-2cfc023cd8d6/Figure+1.jpg Concepts and Principles - Advanced Drug Modalities Part 1: Cell Therapies - Make it stand out Figure 1. Cell immunotherapies. A. On the left, the main stages of dendritic cell autologous cell therapy. Immature dendritic cells (DCs) isolated from a patient undergo maturation after which they are loaded with cancer antigens and administered into the same patient. On the right, the main stages of chimeric antigen receptor T-cell (CAR-T) therapy. T-cell isolated from patients are engineered (reprogrammed) to express a CAR for a specific cancer antigen and after CAR-T cells undergo multiplication are administered into patients. A single CAR is depicted, with its extracellular antigen binding domain in green and the intracellular signaling domain in orange. B. The overall architecture of a CAR. Colors as in A. https://images.squarespace-cdn.com/content/v1/653536fc271ea56714ee90c6/e1c2a902-4021-4c58-ad60-4f8e382f54f8/Table1.jpg Concepts and Principles - Advanced Drug Modalities Part 1: Cell Therapies - Make it stand out Table 1. List of approved CAR-T therapies, together with their indications and year of approval. https://drugdiscoveryandbiotech.com/principles-and-concepts/established-drug-modalities-part-3-protein-and-peptide-modalities monthly 0.5 2024-03-14 https://drugdiscoveryandbiotech.com/principles-and-concepts/overview-of-established-drug-modalities-part-2-monoclonal-antibodies monthly 0.5 2024-03-14 https://images.squarespace-cdn.com/content/v1/653536fc271ea56714ee90c6/8a6b2cfd-e2f5-4b65-9b8d-15a18d2c6c8c/Figure_2.jpg Concepts and Principles - Established Drug Modalities Part 2: Monoclonal Antibodies - Make it stand out Figure 1. The structure of monoclonal antibodies (mAbs). A. Cartoon representation of a mAb. LC – light chain, in orange; HC – heavy chain, in red. B. The crystal structure of Keytruda (PDB code 5DK3). Secondary structures are show in cartoon representation. Colors as in A. Aspirin is shown to illustrate the difference in size between a small molecule drug and an antibody. https://drugdiscoveryandbiotech.com/principles-and-concepts/drug-modalities-overview-from-established-pillars-to-emerging-frontiers-part-1-established-drug-modalities monthly 0.5 2025-01-08 https://images.squarespace-cdn.com/content/v1/653536fc271ea56714ee90c6/034db578-6864-47cf-9891-d4b80233030d/Figure_1.jpg Concepts and Principles - Established Drug Modalities Part 1: Small Molecule Drug Modalities - Make it stand out Figure 1. Examples of small molecule drugs with tremendous impact in medicine. A. Aspirin. B. Penicillin G. C. Retrovir. D. Lovastatin. The structures were generated with RCSB’s chemical sketch tool, available at https://www.rcsb.org/chemical-sketch. https://drugdiscoveryandbiotech.com/home daily 1.0 2026-01-25 https://drugdiscoveryandbiotech.com/filip-yabukarski daily 0.75 2026-01-25 https://images.squarespace-cdn.com/content/v1/653536fc271ea56714ee90c6/8a3ca510-35a2-4f23-9e5c-65c7c7c895b5/Filip+Yabukarski.jpg https://drugdiscoveryandbiotech.com/drug-discovery-overview daily 0.75 2024-07-28 https://drugdiscoveryandbiotech.com/biotech-investing daily 0.75 2025-07-26 https://drugdiscoveryandbiotech.com/learning-resources/drug-discovery daily 0.75 2024-02-18 https://images.squarespace-cdn.com/content/v1/653536fc271ea56714ee90c6/2c0fe9aa-9bc2-4fda-a330-ef77bcb2f605/9131-CeTG9L._AC_UL600_SR600%2C600_.jpg https://drugdiscoveryandbiotech.com/learning-resources/drug-discovery-terms-and-definitions daily 0.75 2024-01-02 https://images.squarespace-cdn.com/content/v1/653536fc271ea56714ee90c6/2c0fe9aa-9bc2-4fda-a330-ef77bcb2f605/9131-CeTG9L._AC_UL600_SR600%2C600_.jpg